1132827-30-5

Basic information

• Product Name: 2-(4-Aminophenyl)imidazo[2,1-b]benzothiazol-7-ol
• Synonyms: 2-(4-Aminophenyl)imidazo[2,1-b]benzothiazol-7-ol;4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)benzenamine;2-(4-aminophenyl)imidazo[2,1-b][1,3]benzothiazol-7-ol
• CAS NO: 1132827-30-5
• Molecular Formula: C₁₅H₁₁N₃OS
• Molecular Weight: 281.33234
• Mol File: 1132827-30-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-Aminophenyl)imidazo[2,1-b]benzothiazol-7-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Aminophenyl)imidazo[2,1-b]benzothiazol-7-ol(1132827-30-5)
• EPA Substance Registry System: 2-(4-Aminophenyl)imidazo[2,1-b]benzothiazol-7-ol(1132827-30-5)

Safety Data

• Hazardous Substances Data: 1132827-30-5(Hazardous Substances Data)

Usage

General Description

2-(4-Aminophenyl)imidazo[2,1-b]benzothiazol-7-ol is a chemical compound with a complex structure that includes an imidazole and benzothiazole ring system. It contains an amine functional group and a hydroxyl group, which makes it potentially useful in pharmaceutical and medicinal applications. The compound's structure suggests potential biological activity and it could be further studied as a potential drug candidate. Its unique chemical structure and potential biological activity make it an interesting compound for further research and development.

Upstream product

• 914224-34-3 2-(4-nitrophenyl)imidazo[2,1-b][1,3]benzothiazol-7-ol 
• 24247-22-1 7-methoxy-2-(4-nitrophenyl)benzo[d]imidazo[2,1-b]thiazole 
• 1206722-59-9 4-(7-methoxyimidazo[2,1-b]benzothiazol-2-yl)benzenamine 
• 1240348-29-1 2-(p-acetamidophenyl)-7-methoxyimidazo[2,1-b]benzothiazole 
• 1747-60-0 6-methoxybenzothiazol-2-ylamine 
• 99-81-0 4-Nitrophenacyl bromide 
• 21675-02-5 4-acetylaminophenacyl bromide 

Downstream Products

• 950769-51-4 N-(5-tert-butylisoxazol-3-yl)-N'-[4-(7-hydroxyimidazo[2,1-b][1,3]benzothiazol-2-yl)phenyl]urea 

Relevant articles and documents

Synthesis and evaluation of 11C-labeled imidazo[2,1-b] benzothiazoles (IBTs) as PET tracers for imaging β-amyloid plaques in Alzheimer's disease

We report a novel series of 11C-labeled imidazo[2,1-b] benzothiazoles (IBTs) as tracers for imaging of cerebral β-amyloid (Aβ) deposits in patients with Alzheimer's disease (AD) by means of positron emission tomography (PET). From a series of 11 compounds, candidates were identified to have a high binding affinity for Aβ. Selected compounds were prepared as O- or N-[11C]methyl derivatives and shown to have a high initial brain uptake in wild-type mice (range 1.9-9.2% I.D./g at 5 min). 2-(p-[11C]Methylaminophenyl)-7-methoxyimidazo[2,1-b] benzothiazole ([11C]5) was identified as a lead based on the combined favorable properties of high initial brain uptake, rapid clearance from normal brain, and high in vitro affinity for Aβ1-40 (Ki = 3.5 nM) and Aβ1-42 (5.8 nM), which were superior to the Pittsburgh compound B (1a). In an APP/PS1 mouse model of AD (Tg), we demonstrate a specific uptake of [11C]5 in Aβ-containing telencephalic brain regions by means of small-animal PET that was confirmed by regional brain biodistribution, ex vivo autoradiography, and immunohistochemistry. Analysis of brain sections of Tg mice receiving a single bolus injection of [11C]5 and [ 3H]1a together revealed that the tracers bind to Aβ plaques in the brain of Tg mice in a comparable pattern. Taken together, these data suggest that IBTs represent useful PET imaging agents for high-sensitivity detection of Aβ plaques.

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2- morpholin-4-yl-ethoxy)imidazo-[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor

Treatment of AML patients with small molecule inhibitors of FLT3 kinase has been explored as a viable therapy. However, these agents are found to be less than optimal for the treatment of AML because of lack of sufficient potency or suboptimal oral pharma